Li Pan, Xiao Zhitao, Braciak Todd A, Ou Qingjian, Chen Gong, Oduncu Fuat S
Department of Hematology and Oncology, Medizinische Klinik und Poliklinik IV, Ludwig Maximilians University, Munich, Germany.
Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
PLoS One. 2017 Mar 2;12(3):e0172799. doi: 10.1371/journal.pone.0172799. eCollection 2017.
The progression of colorectal cancer (CRC) may differ depending on the location of the tumor and the age of onset of the disease. Previous studies also suggested that the molecular basis of CRC varies with tumor location, which could affect the clinical management of patients. Therefore, we performed survival analysis looking at different age groups and mismatch repair status (MMR) of CRC patients according to primary tumor location in an attempt to identify subgroups of CRC that might help in the prognosis of disease.
A group of 2233 patients operated on to remove their CRC tumors were analyzed (521 with right colon cancer, 740 with left colon cancer and 972 with rectal cancer). The expression of four MMR genes was assessed by immunohistochemistry (IHC), independent of clinical criteria. From the data collected, a predictive model for overall survival (OS) could be constructed for some associations of tumor location and age of onset using Kaplan-Meier, logistic and Cox regression analysis.
When tumor location was considered as the lone factor, we found no statistical difference in overall survival (OS) between right cancer (68%), left cancer (67%) or rectal cancer tumor locations (71%) (HR: 1.17, 95%CI (confidence interval): 0.97-1.43, P = 0.057). When age of onset was considered, middle age (40-59 years) and older (60-85 years) patients were found to have higher OS than younger onset cancer (20-39 years) patients (69% vs 71% vs 59%, HR: 1.07, 95% confidence interval (CI): 0.91-1.25, P = 0.008). When both age of onset and tumor location were considered in combination as disease factors, we found that the subgroup of patients with left colon cancer from middle age (69%) and older (67%) aged patients had higher OS than younger (54%) patients (HR: 0.89, 95%CI: 0.68-1.16, P = 0.048). However in patients with right colon cancers, we found no statistical difference is OS between younger, middle age or older grouped patients (60% vs 71% vs 67%, HR: 0.84, 95% CI: 0.61-1.16, P = 0.194). With regard to rectal located cancers, we found that younger (62%) and middle age (68) patients had lower OS than older (77%) patients (HR:1.46, 95%CI: 1.13-1.88, P = 0.004). The rates of deficient MMR (dMMR) was 10.4%. We found no statistical difference in OS stratified by tumor locations. However, right colon cancer patients with dMMR (86%) had higher OS than those with proficient MMR (pMMR) (63%) (HR: 3.01, 95% CI: 1.82-4.97, P<0.001). Left colon cancer patients with dMMR (76%) also had higher OS than those with pMMR (66%) (HR: 1.67, 95% CI: 0.95-2.92, P = 0.01). Oppositely, rectal cancer patients with dMMR (60%) had lower OS than those pMMR (68%) (HR: 0.77, 95% CI: 0.51-1.17, P = 0.04).
These data demonstrate that primary tumor location can be an important factor when considered along with age of onset for the prognosis of CRC. Primary tumor location is also an important factor to evaluate the predictive effect of MMR status for the prognosis of CRC.
结直肠癌(CRC)的进展可能因肿瘤位置和发病年龄而异。先前的研究还表明,CRC的分子基础随肿瘤位置而变化,这可能会影响患者的临床管理。因此,我们根据原发肿瘤位置对不同年龄组和错配修复状态(MMR)的CRC患者进行了生存分析,试图确定可能有助于疾病预后的CRC亚组。
分析了一组2233例接受CRC肿瘤切除手术的患者(521例右结肠癌患者,740例左结肠癌患者和972例直肠癌患者)。通过免疫组织化学(IHC)评估四个MMR基因的表达,与临床标准无关。从收集的数据中,可以使用Kaplan-Meier、逻辑回归和Cox回归分析为肿瘤位置和发病年龄的某些关联构建总生存(OS)预测模型。
当将肿瘤位置视为唯一因素时,我们发现右结肠癌(68%)、左结肠癌(67%)或直肠癌肿瘤位置(71%)之间的总生存(OS)无统计学差异(HR:1.17,95%CI(置信区间):0.97-1.43,P = 0.057)。当考虑发病年龄时,发现中年(40-59岁)和老年(60-85岁)患者的OS高于发病年龄较小(20-39岁)的患者(69%对71%对59%,HR:1.07,95%置信区间(CI):0.91-1.25,P = 0.008)。当将发病年龄和肿瘤位置作为疾病因素综合考虑时,我们发现中年(69%)和老年(67%)的左结肠癌患者亚组的OS高于年轻患者(54%)(HR:0.89,95%CI:0.68-1.16,P = 0.048)。然而,在右结肠癌患者中,我们发现年轻、中年或老年分组患者之间的OS无统计学差异(60%对71%对67%,HR:0.84,95%CI:0.61-1.16,P = 0.194)。关于直肠癌,我们发现年轻(62%)和中年(68%)患者的OS低于老年(77%)患者(HR:1.46,95%CI:1.13-1.88,P = 0.004)。错配修复缺陷(dMMR)率为10.4%。我们发现按肿瘤位置分层的OS无统计学差异。然而,dMMR的右结肠癌患者(86%)的OS高于错配修复功能正常(pMMR)的患者(63%)(HR:3.01,95%CI:1.82-4.97,P<0.001)。dMMR的左结肠癌患者(76%)的OS也高于pMMR的患者(66%)(HR:1.67,95%CI:0.95-2.92,P = 0.01)。相反,dMMR的直肠癌患者(60%)的OS低于pMMR的患者(68%)(HR:0.77,95%CI:0.51-1.17,P = 0.04)。
这些数据表明,在考虑CRC预后时,原发肿瘤位置与发病年龄一起可能是一个重要因素。原发肿瘤位置也是评估MMR状态对CRC预后预测效果的重要因素。